Last reviewed · How we verify

Intravenous anesthetic

University of Pennsylvania · FDA-approved active Small molecule

Intravenous anesthetics work by enhancing inhibitory GABAergic neurotransmission and/or blocking excitatory glutamatergic signaling in the central nervous system to produce rapid unconsciousness.

Intravenous anesthetics work by enhancing inhibitory GABAergic neurotransmission and/or blocking excitatory glutamatergic signaling in the central nervous system to produce rapid unconsciousness. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units.

At a glance

Generic nameIntravenous anesthetic
SponsorUniversity of Pennsylvania
Drug classGABA-A receptor agonist / NMDA receptor antagonist (class-dependent)
TargetGABA-A receptor or NMDA receptor (varies by specific agent)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Most IV anesthetics (such as propofol, etomidate, and thiopental) are positive allosteric modulators of GABA-A receptors, increasing chloride influx and neuronal hyperpolarization. Some agents like ketamine act as non-competitive NMDA receptor antagonists. These mechanisms collectively suppress cortical activity and consciousness within seconds of administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: